(Q35636536)

9 August 2017

1 reference

title

Matrix metalloproteinase inhibitor development and the remodeling of drug discovery (English)

1 reference

9 August 2017

1 reference

J Thomas Peterson

1

1 reference

PubMed ID

14739769

9 August 2017

language of work or name

1 reference

1 January 2004

1 reference

9 August 2017

Heart Failure Reviews

1 reference

9 August 2017

9

1 reference

9 August 2017

1

1 reference

9 August 2017

63-79

1 reference

https://scigraph.springernature.com/pub.10.1023/b:hrev.0000011395.11179.af

9 August 2017

0 references

cites work

Thirty-six years in the clinic without an MMP inhibitor. What hath collagenase wrought?

1 reference

12 December 2020

The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter

1 reference

12 December 2020

Increasing throughput in lead optimization in vivo toxicity screens

1 reference

12 December 2020

Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study.

1 reference

12 December 2020

Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors

1 reference

12 December 2020

Design and therapeutic application of matrix metalloproteinase inhibitors

1 reference

12 December 2020

Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor

1 reference

12 December 2020

Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure

1 reference

12 December 2020

The use of fibrates and of statins in preventing atherosclerosis in diabetes

1 reference

12 December 2020

1 reference

12 December 2020

Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3.

1 reference

12 December 2020

Preclinical and clinical studies of MMP inhibitors in cancer

1 reference

12 December 2020

Degradation of cartilage proteoglycans by a neutral proteinase secreted by rabbit bone-marrow macrophages in culture

1 reference

12 December 2020

Tissue inhibitor of metalloproteinases (TIMP-1) stimulates the secretion of collagenase from human skin fibroblasts

1 reference

12 December 2020

MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes

1 reference

12 December 2020

Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice

1 reference

12 December 2020

Periodontal disease and cardiovascular disease

1 reference

12 December 2020

Ongoing trials with matrix metalloproteinase inhibitors

1 reference

12 December 2020

Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1

1 reference

12 December 2020

Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice

1 reference

12 December 2020

Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance

1 reference

12 December 2020

Purification and characterization of the human stromelysin catalytic domain expressed in Escherichia coli

1 reference

12 December 2020

Low-dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans

1 reference

12 December 2020

Subantimicrobial dose doxycycline as an adjunct to scaling and root planing: post-treatment effects

1 reference

12 December 2020

Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing

1 reference

12 December 2020

MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover

1 reference

12 December 2020

A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer

1 reference

12 December 2020

1 reference

12 December 2020

Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats

1 reference

12 December 2020

Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study

1 reference

12 December 2020

Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis.

1 reference

12 December 2020

Overview of risk factors for periodontal disease and implications for diabetes and cardiovascular disease.

1 reference

12 December 2020

Development of matrix metalloproteinase inhibitors in cancer therapy.

1 reference

12 December 2020

Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro

1 reference

12 December 2020

MMP inhibition in prostate cancer

1 reference

12 December 2020

Marimastat in patients with advanced pancreatic cancer: a dose-finding study

1 reference

12 December 2020

Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome

1 reference

12 December 2020

Tetracycline and its derivatives strongly bind to and are released from the tooth surface in active form

1 reference

12 December 2020

A recombinant human stromelysin catalytic domain identifying tryptophan derivatives as human stromelysin inhibitors.

1 reference

12 December 2020

Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response

1 reference

12 December 2020

Collagenase induction promotes mouse tumorigenesis by two independent pathways

1 reference

12 December 2020

Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure

1 reference

12 December 2020

Impact of mobility on structure-based drug design for the MMPs

1 reference

12 December 2020

Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells

1 reference

12 December 2020

Drug design strategies for targeting G-protein-coupled receptors

1 reference

12 December 2020

Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice

1 reference

12 December 2020

Characterization of C-terminally truncated human tissue inhibitor of metalloproteinases-4 expressed in Pichia pastoris

1 reference

12 December 2020

Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury

1 reference

12 December 2020

Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A

1 reference

12 December 2020

The effects of sustained elevated levels of circulating tissue inhibitor of metalloproteinases-1 on the development of breast cancer in mice.

1 reference

12 December 2020

Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor.

1 reference

12 December 2020

Collagenase-2 (MMP-8) and collagenase-3 (MMP-13) in adult periodontitis: molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue

1 reference

12 December 2020

Expression and Prognostic Significance of Metalloproteinases and Their Tissue Inhibitors in Patients With Small-Cell Lung Cancer

1 reference

12 December 2020

Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells

1 reference

12 December 2020

Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line

1 reference

12 December 2020

A protocol for rapid screening of proteoglycan-degrading metalloproteinase inhibitors

1 reference

12 December 2020

Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model

1 reference

12 December 2020

Protease inhibitors: role and potential therapeutic use in human cancer

1 reference

12 December 2020

Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization

1 reference

12 December 2020

Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.

1 reference

12 December 2020

Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.

1 reference

12 December 2020

Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice

1 reference

12 December 2020

Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effe

1 reference

12 December 2020

Contribution of the C-terminal domain of metalloproteinases to binding by tissue inhibitor of metalloproteinases. C-terminal truncated stromelysin and matrilysin exhibit equally compromised binding affinities as compared to full-length stromelysin

1 reference

12 December 2020

The impact of new technologies on drug design

1 reference

12 December 2020

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

1 reference

12 December 2020

MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis

1 reference

12 December 2020

Uptake of tetracycline by aortic aneurysm wall and its effect on inflammation and proteolysis.

1 reference

12 December 2020

MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial

1 reference

12 December 2020

Disruption of the myocardial extracellular matrix leads to cardiac dysfunction

1 reference

12 December 2020

Tumour marker levels during marimastat therapy

1 reference

12 December 2020

Identification of periodontal pathogens in atheromatous plaques.

1 reference

12 December 2020

Periodontal disease as a risk factor for heart disease

1 reference

12 December 2020

Hit and lead generation: beyond high-throughput screening

1 reference

12 December 2020

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.

1 reference

12 December 2020

Clinical biomarkers in drug discovery and development

1 reference

12 December 2020

10.1023/B:HREV.0000011395.11179.AF

Identifiers

DOI

1 reference

PubMed ID

14739769

Dimensions Publication ID

9 August 2017

0 references

1 reference

PubMed ID

14739769